BJC:HIF-1α預(yù)測膀胱癌受益于放療-CON聯(lián)合治療

來源:百濟(jì)藥房藥訊   2016-05-08
導(dǎo)讀:曼徹斯特的科學(xué)家發(fā)現(xiàn)了一種蛋白質(zhì),可以幫助醫(yī)生確定哪些膀胱癌患者將受益于治療,研究結(jié)果發(fā)表在英國癌癥雜志(BJC)雜志上。

  
  來自曼徹斯特大學(xué)的團(tuán)隊(duì)發(fā)現(xiàn)膀胱腫瘤患者有較高水平的蛋白質(zhì)HIF-1α,更有可能受益于一種治療方法,即在放療的同時(shí)給予患者混和氧(95%O2、5%CO2的混合氣體)和煙酰胺片。這種治療方法被稱為"CON",能使放射放療更有效。

  通過比較,單獨(dú)放療或放療與CON聯(lián)合治療患者腫瘤組織樣本中HIF-1α的水平,研究人員發(fā)現(xiàn)該蛋白能預(yù)測哪些患者受益于CON。當(dāng)患者接受放療和CON,高濃度的蛋白質(zhì)與疾病更好的生存有關(guān)聯(lián)。低蛋白水平患者并沒有受益于CON與組合放射治療。

  doi:10.1038/bjc.2014.315

  PMC:

  PMID:

  Expression hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer

  Hunter, BA et al.

  Background:

  The addition of carbogen and nicotinamide (CON) to radiotherapy (RT) improves overall survival in invasive bladder cancer. We explored whether expression of the hypoxia marker hypoxia-inducible factor-1α (HIF-1α) alone or in combination with other markers predicted benefit from CON.

  Methods:

  A retrospective study was carried out using material from patients with high-grade invasive bladder carcinoma enrolled in the BCON phase III trial of RT alone or with CON (RT+CON). HIF-1α expression was studied in 137 tumours using tissue microarrays and immunohistochemistry. Data were available from other studies for carbonic anhydrase IX and glucose transporter 1 protein and gene expression and tumour necrosis.

  Results:

  Patients with high HIF-1α expression had improved 5-year local relapse-free survival with RT+CON (47%) compared with RT alone (21%; hazard ratio (HR) 0.48, 95% CI 0.26-0.8, P=0.02), no benefit was seen with low HIF-1α expression (HR 0.81, 95% CI 0.43-1.50, P=0.5). Combinations of markers including necrosis also predicted benefit but did not improve on prediction using necrosis alone.

  Conclusions:

  HIF-1α may be used to predict benefit from CON in patients with bladder cancer but does not improve on use of necrosis.

  膀胱癌如何治療?膀胱癌的治療藥物可以選擇:復(fù)方皂礬丸、艾諾克、西黃膠囊等藥物進(jìn)行輔助治療。

  詳情請致電我們的客服垂詢:400-101-6868。如需購買復(fù)方皂礬丸、艾諾克、西黃膠囊,可到臨近門店。廣州腫瘤店地址為:廣州市越秀區(qū)先烈南路21號之一(中山大學(xué)腫瘤醫(yī)院中門斜對面)。通過GSP質(zhì)量認(rèn)證的藥房,獲"廣州市藥品經(jīng) 營誠信企業(yè)"和工商局頒發(fā)的"消費(fèi)者信得過商家"稱號。門店電話:020-87303808。

  腫瘤科藥師溫馨提醒:膀胱癌的發(fā)病是一個(gè)多因素混合、多基因參與、多步驟形成的過程,異?;蛐偷姆e累加上外在環(huán)境的作用終導(dǎo)致惡性表型的出現(xiàn)。

【溫馨提示】本網(wǎng)站內(nèi)容僅供參考,一切診斷和治療請遵從醫(yī)生的指導(dǎo)。

● 如果您有任何疑問,請聯(lián)系我們。
● 如需咨詢藥物,請點(diǎn)擊【服務(wù)指南】,了解相關(guān)信息。

膀胱癌藥物
本欄目熱點(diǎn)文章

藥品信息服務(wù)證: (粵)一非經(jīng)營性一2018—0148
@2013~2024 廣州市康維信息技術(shù)有限公司 版權(quán)所有

服務(wù)熱線:400-101-6868
請輸入搜索關(guān)鍵詞